A citation-based method for searching scientific literature

Snjezana Dogan, Ronglai Shen, Daphne C Ang, Melissa L Johnson, Sandra P D'Angelo, Paul K Paik, Edyta B Brzostowski, Gregory J Riely, Mark G Kris, Maureen F Zakowski, Marc Ladanyi. Clin Cancer Res 2012
Times Cited: 387







List of co-cited articles
1004 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
869
36

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
774
33

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.
David S Hong, Marwan G Fakih, John H Strickler, Jayesh Desai, Gregory A Durm, Geoffrey I Shapiro, Gerald S Falchook, Timothy J Price, Adrian Sacher, Crystal S Denlinger,[...]. N Engl J Med 2020
620
33

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, David M Briere, Niranjan Sudhakar, Vickie Bowcut, Brian R Baer, Joshua A Ballard,[...]. Cancer Discov 2020
532
27

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Ferdinandos Skoulidis, Lauren A Byers, Lixia Diao, Vassiliki A Papadimitrakopoulou, Pan Tong, Julie Izzo, Carmen Behrens, Humam Kadara, Edwin R Parra, Jaime Rodriguez Canales,[...]. Cancer Discov 2015
522
24


Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, Timothy J Price, Gerald S Falchook, Jürgen Wolf, Antoine Italiano, Martin Schuler, Hossein Borghaei, Fabrice Barlesi,[...]. N Engl J Med 2021
349
22

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.
Jonathan M Ostrem, Ulf Peters, Martin L Sos, James A Wells, Kevan M Shokat. Nature 2013
21

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
Zhong-Yi Dong, Wen-Zhao Zhong, Xu-Chao Zhang, Jian Su, Zhi Xie, Si-Yang Liu, Hai-Yan Tu, Hua-Jun Chen, Yue-Li Sun, Qing Zhou,[...]. Clin Cancer Res 2017
542
20

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.
Badi El Osta, Madhusmita Behera, Sungjin Kim, Lynne D Berry, Gabriel Sica, Rathi N Pillai, Taofeek K Owonikoko, Mark G Kris, Bruce E Johnson, David J Kwiatkowski,[...]. J Thorac Oncol 2019
97
19

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer.
Kathryn C Arbour, Emmett Jordan, Hyunjae Ryan Kim, Jordan Dienstag, Helena A Yu, Francisco Sanchez-Vega, Piro Lito, Michael Berger, David B Solit, Matthew Hellmann,[...]. Clin Cancer Res 2018
210
19

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.
Ferdinandos Skoulidis, John V Heymach. Nat Rev Cancer 2019
340
19

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Matthew R Janes, Jingchuan Zhang, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Xin Guo, Yuching Chen, Anjali Babbar, Sarah J Firdaus, Levan Darjania,[...]. Cell 2018
582
18

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Matthias Scheffler, Michaela A Ihle, Rebecca Hein, Sabine Merkelbach-Bruse, Andreas H Scheel, Janna Siemanowski, Johannes Brägelmann, Anna Kron, Nima Abedpour, Frank Ueckeroth,[...]. J Thorac Oncol 2019
113
16

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
Emmet J Jordan, Hyunjae R Kim, Maria E Arcila, David Barron, Debyani Chakravarty, JianJiong Gao, Matthew T Chang, Andy Ni, Ritika Kundra, Philip Jonsson,[...]. Cancer Discov 2017
358
15

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Matthew P Patricelli, Matthew R Janes, Lian-Sheng Li, Rasmus Hansen, Ulf Peters, Linda V Kessler, Yuching Chen, Jeff M Kucharski, Jun Feng, Tess Ely,[...]. Cancer Discov 2016
425
15

RAS Proteins and Their Regulators in Human Disease.
Dhirendra K Simanshu, Dwight V Nissley, Frank McCormick. Cell 2017
803
15

Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
Nathan T Ihle, Lauren A Byers, Edward S Kim, Pierre Saintigny, J Jack Lee, George R Blumenschein, Anne Tsao, Suyu Liu, Jill E Larsen, Jing Wang,[...]. J Natl Cancer Inst 2012
351
14

The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Chengming Liu, Sufei Zheng, Runsen Jin, Xinfeng Wang, Feng Wang, Ruochuan Zang, Haiyan Xu, Zhiliang Lu, Jianbing Huang, Yuanyuan Lei,[...]. Cancer Lett 2020
125
13

Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition.
Meagan B Ryan, Ferran Fece de la Cruz, Sarah Phat, David T Myers, Edmond Wong, Heather A Shahzade, Catriona B Hong, Ryan B Corcoran. Clin Cancer Res 2020
161
13

Drugging the undruggable RAS: Mission possible?
Adrienne D Cox, Stephen W Fesik, Alec C Kimmelman, Ji Luo, Channing J Der. Nat Rev Drug Discov 2014
13

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
Arnaud Jeanson, Pascale Tomasini, Maxime Souquet-Bressand, Nicolas Brandone, Mohamed Boucekine, Mathieu Grangeon, Solène Chaleat, Natalyia Khobta, Julie Milia, Laurent Mhanna,[...]. J Thorac Oncol 2019
101
13

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
507
13

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
13

Acquired Resistance to KRASG12C Inhibition in Cancer.
Mark M Awad, Shengwu Liu, Igor I Rybkin, Kathryn C Arbour, Julien Dilly, Viola W Zhu, Melissa L Johnson, Rebecca S Heist, Tejas Patil, Gregory J Riely,[...]. N Engl J Med 2021
188
13

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.
Pasi A Jänne, Michel M van den Heuvel, Fabrice Barlesi, Manuel Cobo, Julien Mazieres, Lucio Crinò, Sergey Orlov, Fiona Blackhall, Juergen Wolf, Pilar Garrido,[...]. JAMA 2017
233
12

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
Gregory J Riely, Mark G Kris, Daniel Rosenbaum, Jenifer Marks, Allan Li, Dhananjay A Chitale, Khedoudja Nafa, Elyn R Riedel, Meier Hsu, William Pao,[...]. Clin Cancer Res 2008
403
12

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
Jenny Y Xue, Yulei Zhao, Jordan Aronowitz, Trang T Mai, Alberto Vides, Besnik Qeriqi, Dongsung Kim, Chuanchuan Li, Elisa de Stanchina, Linas Mazutis,[...]. Nature 2020
196
12


Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Jean-Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, Thanyanan Reungwetwattana, Busyamas Chewaskulyong, Ki Hyeong Lee, Arunee Dechaphunkul, Fumio Imamura, Naoyuki Nogami, Takayasu Kurata,[...]. N Engl J Med 2018
11

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
11

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.
Piro Lito, Martha Solomon, Lian-Sheng Li, Rasmus Hansen, Neal Rosen. Science 2016
384
11

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
10

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
10

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
Mark G Kris, Bruce E Johnson, Lynne D Berry, David J Kwiatkowski, A John Iafrate, Ignacio I Wistuba, Marileila Varella-Garcia, Wilbur A Franklin, Samuel L Aronson, Pei-Fang Su,[...]. JAMA 2014
10

RAS oncogenes: the first 30 years.
Marcos Malumbres, Mariano Barbacid. Nat Rev Cancer 2003
10

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
10

KRAS-Mutant non-small cell lung cancer: From biology to therapy.
Irene Ferrer, Jon Zugazagoitia, Stephan Herbertz, William John, Luis Paz-Ares, Gerald Schmid-Bindert. Lung Cancer 2018
155
10

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
Frances A Shepherd, Caroline Domerg, Pierre Hainaut, Pasi A Jänne, Jean-Pierre Pignon, Stephen Graziano, Jean-Yves Douillard, Elizabeth Brambilla, Thierry Le Chevalier, Lesley Seymour,[...]. J Clin Oncol 2013
212
10

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.
Sara Mainardi, Antonio Mulero-Sánchez, Anirudh Prahallad, Giovanni Germano, Astrid Bosma, Paul Krimpenfort, Cor Lieftink, Jeffrey D Steinberg, Niels de Wit, Samuel Gonçalves-Ribeiro,[...]. Nat Med 2018
186
10

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
10

A comprehensive survey of Ras mutations in cancer.
Ian A Prior, Paul D Lewis, Carla Mattos. Cancer Res 2012
10

RAS-targeted therapies: is the undruggable drugged?
Amanda R Moore, Scott C Rosenberg, Frank McCormick, Shiva Malek. Nat Rev Drug Discov 2020
317
10

Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation.
Noritaka Tanaka, Jessica J Lin, Chendi Li, Meagan B Ryan, Junbing Zhang, Lesli A Kiedrowski, Alexa G Michel, Mohammed U Syed, Katerina A Fella, Mustafa Sakhi,[...]. Cancer Discov 2021
107
10

Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Yuta Adachi, Kentaro Ito, Yuko Hayashi, Ryo Kimura, Tuan Zea Tan, Rui Yamaguchi, Hiromichi Ebi. Clin Cancer Res 2020
66
15

Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors.
Brian A Lanman, Jennifer R Allen, John G Allen, Albert K Amegadzie, Kate S Ashton, Shon K Booker, Jian Jeffrey Chen, Ning Chen, Michael J Frohn, Guy Goodman,[...]. J Med Chem 2020
192
9

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
Hisayuki Shigematsu, Li Lin, Takao Takahashi, Masaharu Nomura, Makoto Suzuki, Ignacio I Wistuba, Kwun M Fong, Huei Lee, Shinichi Toyooka, Nobuyoshi Shimizu,[...]. J Natl Cancer Inst 2005
9

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Tony S Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose,[...]. N Engl J Med 2009
9

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Yuankai Shi, Joseph Siu-Kie Au, Sumitra Thongprasert, Sankar Srinivasan, Chun-Ming Tsai, Mai Trong Khoa, Karin Heeroma, Yohji Itoh, Gerardo Cornelio, Pan-Chyr Yang. J Thorac Oncol 2014
846
9

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.